Roche Pharma (Schwiez) AG is a member of Roche Group domiciled in Reinach (BL) and covers the areas of Marketing & Sales, Medical Affairs and registration and quality assurance of medicines from Roche in Switzerland. The affiliate consists of 150 people from over 8 nations/
Covering the fields of oncology, rheumatology, pulmonology and neurology, Roche’s top priority is to ensure access to innovative care for patients with serious or life-threatening diseases.
Since an accelerated approval procedure was introduced 2010, 11 Innovative products and indications approved by Swissmedic
> 100 Clinical studies in Switzerland with more than 2,000 patients since 2000
As a healthcare partner, Roche Pharma AG is an important link in the chain of the path of a drug from the research and approval through to delivery to the patient, and is fully responsible for daily operations including the provision of expertise on drugs, planning and management of clinical trials, negotiations on approvals and reimbursement prices in Switzerland as well as ensuring the availability, safety and quality of marketed drugs.
Contact
Roche Pharma (Schweiz) AG
Schönmattstrasse 2
CH-4153 Reinach BL
+41 61 715 41 11
As the home market, Switzerland and Roche’s Swiss pharma operations play an important and pioneering role within Roche’s global organization, with early patient access to innovation and new commercial models…
While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022…
The biggest pharma news from Switzerland, including the industry’s cautious reaction to a new free trade deal with India; the drop in Roche’s share prices; Novartis’ acquisiton of MorphoSys, and…
For the Swiss Agency for Therapeutic Products (Swissmedic), one of the world’s leading regulatory authorities, 2023 was an important year. Not only did the agency gain recognition from the World…
Obesity is pharma’s new El Dorado. Following the spectacular market success and sky-high sales projections of next-generation obesity treatments, many actors – both large and small – are looking to…
2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated…
As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment…
At this year’s Swiss Biotech Day, the Swiss Biotech Association celebrated its 25 years of existence and proved the ability of the sector to weather geopolitical disruptions and funding challenges…
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Executive…
The latest news from Swiss pharma and healthcare, including the startling announcement that Switzerland is set to destroy a full nine million doses of expired Moderna COVID-19 vaccines, with over…
Roche slipped from second to fifth place in this year’s ranking of the world’s top pharmaceutical companies, reported uninspiring numbers for the first half of the year and seen its…
After a Moderna-Lonza production site and a Merck manufacturing facility were set up in western Switzerland, the country continues to attract big pharma capital with a CHF 200 million investment…
Lonza’s global head of Mammalian Biologics, Jennifer Cannon, talks about disruption in the CDMO industry, explains how the Swiss giant is reimagining new models based on risk-sharing, and goes through…
See our Cookie Privacy Policy Here
